About Peplib
Peplib is a company based in Boston (United States) founded in 2017 by Li Sean, Cheng Lei, and Gong Huanzhang. Peplib has raised $34.22 million across 1 funding round from investors including Fortune Capital, CAS Investment Partners and CDH. Peplib operates in a competitive market with competitors including Liberation Labs, NJ Bio, Kinaxo Biotechnologies, Shantani Proteome Analytics and Scala Biodesign, among others.
- Headquarter Boston, United States
- Founders Li Sean, Cheng Lei, Gong Huanzhang
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$34.22 M (USD)
in 1 rounds
-
Latest Funding Round
$34.22 M (USD), Series A
May 12, 2021
-
Investors
Fortune Capital
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Peplib
Unlock access to complete
Unlock access to complete
Funding Insights of Peplib
Peplib has successfully raised a total of $34.22M through 1 strategic funding round. The most recent funding activity was a Series A round of $34.22 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Peplib
Peplib has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Fortune Capital, CAS Investment Partners and CDH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and private debt firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Healthcare startups are funded by HLC venture capital firm.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Peplib
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Peplib
Investment portfolio details for Peplib
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Peplib
Detailed financials for Peplib
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Peplib Comparisons
Peer comparison for Peplib
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Peplib
Peplib operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Liberation Labs, NJ Bio, Kinaxo Biotechnologies, Shantani Proteome Analytics and Scala Biodesign, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Fermentation products are manufactured and commercialized via CRO services.
|
|
| Locked | Locked | Locked |
Clinical development services are provided for biotechnology applications.
|
|
| Locked | Locked | Locked |
Chemical proteomics for cellular target profiling and drug discovery services
|
|
| Locked | Locked | Locked |
Drug discovery services are delivered via chemical-proteomics technologies.
|
|
| Locked | Locked | Locked |
Computational protein design solutions are delivered at scale.
|
Detailed competitors of Peplib
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Peplib
Complete news archive for Peplib
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Peplib
Peplib was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Peplib is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Peplib is a funded company, having raised a total of $34.22M across 1 funding round to date.
Peplib was founded in 2017 in Boston, United States, within the biotech sector. Services in peptide drug discovery and development are offered to global pharmaceutical and biotech companies. A novel technology platform based on cyclic peptides is employed to encode and compress information, supporting drug innovation processes. Operations focus on advancing peptide-based therapeutics for industry partners.
Peplib's top competitors include Liberation Labs, NJ Bio and Shantani Proteome Analytics.
Peplib has 6 investors. Key investors include Fortune Capital, CAS Investment Partners, CDH, Honghui Fund, and Cowin Capital.